Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Advancements in Liver Fibrosis: Diagnostics to Personalized Care

Dr. Oliver T. Becker*
Heidelberg Institute of Biochemical Research, Germany
*Corresponding Author: Dr. Oliver T. Becker, Heidelberg Institute of Biochemical Research, Germany, Email: o.becker@heidelbergbio.de

Citation:

Copyright:

 
To read the full article Peer-reviewed Article PDF image

Abstract

Liver fibrosis research is advancing, focusing on noninvasive diagnostics, including serological markers and imaging, to personalize patient care [1]. Key areas involve understanding inflammation and Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) in driving fibrosis, alongside exploring novel molecular, epigenetic, and gut microbiota-targeted therapies [2, 3, 4, 6, 8]. Biomarkers, Artificial Intelligence (AI), and single-cell sequencing are enhancing diagnostic precision and unraveling cellular complexities [5, 7, 9]. Despite ongoing challenges, future perspectives emphasize personalized medicine and integrated advanced technologies to improve management outcomes

Top Connection closed successfully.